Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain
Executive Summary
AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.